EP3077546A4 - Identification de biomarqueurs predictifs associes a des inhibiteurs de la voie wnt - Google Patents

Identification de biomarqueurs predictifs associes a des inhibiteurs de la voie wnt Download PDF

Info

Publication number
EP3077546A4
EP3077546A4 EP14867583.8A EP14867583A EP3077546A4 EP 3077546 A4 EP3077546 A4 EP 3077546A4 EP 14867583 A EP14867583 A EP 14867583A EP 3077546 A4 EP3077546 A4 EP 3077546A4
Authority
EP
European Patent Office
Prior art keywords
identification
wnt pathway
pathway inhibitors
biomarkers associated
predictive biomarkers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP14867583.8A
Other languages
German (de)
English (en)
Other versions
EP3077546A1 (fr
Inventor
Ann M. Kapoun
Chun Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncomed Pharmaceuticals Inc
Original Assignee
Oncomed Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncomed Pharmaceuticals Inc filed Critical Oncomed Pharmaceuticals Inc
Publication of EP3077546A1 publication Critical patent/EP3077546A1/fr
Publication of EP3077546A4 publication Critical patent/EP3077546A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP14867583.8A 2013-12-02 2014-12-02 Identification de biomarqueurs predictifs associes a des inhibiteurs de la voie wnt Withdrawn EP3077546A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361910663P 2013-12-02 2013-12-02
US201461975339P 2014-04-04 2014-04-04
PCT/US2014/068097 WO2015084808A1 (fr) 2013-12-02 2014-12-02 Identification de biomarqueurs predictifs associes a des inhibiteurs de la voie wnt

Publications (2)

Publication Number Publication Date
EP3077546A1 EP3077546A1 (fr) 2016-10-12
EP3077546A4 true EP3077546A4 (fr) 2017-04-26

Family

ID=53274023

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14867583.8A Withdrawn EP3077546A4 (fr) 2013-12-02 2014-12-02 Identification de biomarqueurs predictifs associes a des inhibiteurs de la voie wnt

Country Status (9)

Country Link
EP (1) EP3077546A4 (fr)
JP (1) JP2017501137A (fr)
CN (1) CN105829547A (fr)
AU (1) AU2014357354A1 (fr)
CA (1) CA2931975A1 (fr)
HK (1) HK1223657A1 (fr)
MX (1) MX2016007066A (fr)
TW (1) TW201610168A (fr)
WO (1) WO2015084808A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
US9359444B2 (en) 2013-02-04 2016-06-07 Oncomed Pharmaceuticals Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
WO2017023971A1 (fr) * 2015-08-03 2017-02-09 Oncomed Pharmaceuticals, Inc. Identification de biomarqueurs prédictifs associés à des inhibiteurs de la voie wnt
MX2018003179A (es) * 2015-09-16 2018-08-21 Tobira Therapeutics Inc Terapia de combinación con cenicriviroc para el tratamiento de fibrosis.
MX2019004940A (es) * 2016-10-26 2019-09-26 Leap Therapeutics Inc Uso de beta-catenina como un biomarcador para el tratamiento de canceres que usan el anticuerpo anti-dkk-1.
CN106990245B (zh) * 2017-04-05 2018-07-31 东南大学 检测pitx1表达量的试剂在制备胃癌预后评估试剂盒中的应用
CN110835372B (zh) * 2019-11-06 2020-12-01 上海健康医学院 一种靶向Frizzled7单克隆抗体及其制备方法与应用
CN111735949B (zh) * 2020-07-17 2023-07-21 北京信诺卫康科技有限公司 Wnt7a和CA125联合用作早期卵巢癌生物标志物以及试剂盒
CN115337400A (zh) * 2021-05-13 2022-11-15 中国科学院分子细胞科学卓越创新中心 诊断和治疗肿瘤的试剂及其用途
CN113293212A (zh) * 2021-06-17 2021-08-24 深圳华因康基因科技有限公司 一种检测神经母细胞瘤复发转移基因fzd2扩增的引物探针及其应用
WO2023113013A1 (fr) * 2021-12-17 2023-06-22 国立大学法人京都大学 Procédé de sélection d'un gène destiné à être utilisé dans l'estimation de la possibilité d'apparition d'une maladie, et procédé d'estimation de la possibilité d'apparition d'une maladie

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010101793A2 (fr) * 2009-03-06 2010-09-10 University Of South Alabama Méthodes et compositions pour le diagnostic, le pronostic et le traitement du cancer
US7982013B2 (en) * 2008-09-26 2011-07-19 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
WO2013086260A2 (fr) * 2011-12-09 2013-06-13 Oncomed Pharmaceuticals, Inc. Thérapie d'association pour le traitement du cancer

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0546073B1 (fr) 1990-08-29 1997-09-10 GenPharm International, Inc. production et utilisation des animaux non humains transgeniques capable de produire des anticorps heterologues
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
JP2003518920A (ja) * 1999-07-02 2003-06-17 カイロン コーポレイション 新規なヒト遺伝子および遺伝子発現産物
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
JP4336498B2 (ja) 2000-12-12 2009-09-30 メディミューン，エルエルシー 延長した半減期を有する分子ならびにその組成物および用途
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
US20040247593A1 (en) * 2002-10-04 2004-12-09 Regents Of The University Of California, Methods for treating cancer by inhibiting Wnt signaling
US7365168B2 (en) 2002-10-15 2008-04-29 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1697415A1 (fr) 2003-11-12 2006-09-06 Biogen Idec MA Inc. Variants de polypeptide se liant au recepteur fc neonatal (fcrn), proteines de liaison fc dimeres et techniques associees
US20080187954A1 (en) 2004-03-10 2008-08-07 Lonza Ltd. Method For Producing Antibodies
WO2006024497A1 (fr) 2004-08-30 2006-03-09 Lonza Biologics Plc. Chromatographie par echange d'ions et affinite pour la purification d'anticorps
CA2628255C (fr) 2005-10-31 2016-04-19 The Regents Of The University Of Michigan Compositions et methodes pour traiter et diagnostiquer un cancer
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
CA2662041A1 (fr) 2006-09-08 2008-03-13 Genentech, Inc. Antagonistes de wnt et leur utilisation pour le diagnostic et le traitement de troubles a mediation wnt
MX2009003229A (es) 2006-09-29 2009-06-18 Oncomed Pharm Inc Composiciones y metodos para diagnosticar y tratar cancer.
EP2084296B1 (fr) * 2006-09-29 2015-08-05 Agendia N.V. Essai diagnostique extremement productif au moyen de jeux ordonnes
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
WO2009092010A1 (fr) 2008-01-18 2009-07-23 Gagnon Peter S Purification améliorée de biomolécules phosphorylées et non phosphorylées par chromatographie sur hydroxyapatite
US20100169025A1 (en) * 2008-10-10 2010-07-01 Arthur William T Methods and gene expression signature for wnt/b-catenin signaling pathway
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
CA2786745A1 (fr) 2010-01-12 2011-07-21 Oncomed Pharmaceuticals, Inc. Agents de liaison a wnt et leurs utilisations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7982013B2 (en) * 2008-09-26 2011-07-19 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
WO2010101793A2 (fr) * 2009-03-06 2010-09-10 University Of South Alabama Méthodes et compositions pour le diagnostic, le pronostic et le traitement du cancer
WO2013086260A2 (fr) * 2011-12-09 2013-06-13 Oncomed Pharmaceuticals, Inc. Thérapie d'association pour le traitement du cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FORGET M-A ET AL: "The Wnt pathway regulator DKKI is preferentially expressed in hormone-resistant breast tumours and in some common cancer types", BRITISH JOURNAL OF CANCER, NATURE PUBLISHING GROUP, GB, vol. 96, 1 January 2007 (2007-01-01), pages 646 - 653, XP003026724, ISSN: 0007-0920, [retrieved on 20070123], DOI: 10.1038/SJ.BJC.6603579 *
See also references of WO2015084808A1 *
WISSMANN C ET AL: "WIFI, A COMPONENT OF THE WNT PATHWAY, IS DOWN-REGULATED IN PROSTATE, BREAST, LUNG, AND BLADDER CANCER", JOURNAL OF PATHOLOGY, JOHN WILEY & SONS LTD, GB, vol. 201, no. 2, 1 January 2003 (2003-01-01), pages 204 - 212, XP008054942, ISSN: 0022-3417, DOI: 10.1002/PATH.1449 *

Also Published As

Publication number Publication date
CN105829547A (zh) 2016-08-03
WO2015084808A4 (fr) 2015-08-13
CA2931975A1 (fr) 2015-06-11
AU2014357354A1 (en) 2016-06-09
JP2017501137A (ja) 2017-01-12
MX2016007066A (es) 2016-09-08
HK1223657A1 (zh) 2017-08-04
EP3077546A1 (fr) 2016-10-12
WO2015084808A1 (fr) 2015-06-11
TW201610168A (zh) 2016-03-16

Similar Documents

Publication Publication Date Title
HRP20190373T1 (hr) Inhibitori dnk-pk
HK1223657A1 (zh) 途徑抑制劑有關的預測性生物標記物的鑒別
EP3011059A4 (fr) Identification de marqueur biologique
HK1223795A1 (zh) 拉喹莫德響應性的基因表達生物標誌物
EP2901333A4 (fr) Pré-mise en cache prédictive de données fondée sur le contexte
HUE037516T2 (hu) DNS-PK inhibitorok
EP3021984A4 (fr) Procédés de mesure de température sur actionneur
EP2991657A4 (fr) Biomarqueurs lipidomiques
EP3024949A4 (fr) Biomarqueurs d'un accouchement prématuré
GB201321474D0 (en) Novel biomarkers
HK1212771A1 (zh) 抑制劑相關之標記
EP2994124A4 (fr) Inhibiteurs d'enzymes métallo-ss-lactamase
EP3036712A4 (fr) Méthodes de prévision de pronostic
IL241063A0 (en) Observe for predictive biomarkers
SG11201600774TA (en) Method of identifying adipose stem cells
EP2970107A4 (fr) Inhibiteurs de hdac photocommutables
EP3079689A4 (fr) Procédé de modulation de divers biomarqueurs à l'aide de curaxines
EP3060305A4 (fr) Biomarqueurs pour perte de mémoire
GB201306339D0 (en) Biomarkers for prognosis
GB201210587D0 (en) Predictive biomarker
GB201308518D0 (en) Novel Biomarker
EP3164717A4 (fr) Biomarqueurs prédictifs
EP3028703A4 (fr) INHIBITEUR DE LA VOIE DE SIGNALISATION Wnt
GB201210571D0 (en) Predictive biomarker
AU2013902243A0 (en) Biomarker identification

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20160621

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

A4 Supplementary search report drawn up and despatched

Effective date: 20170329

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20170323BHEP

Ipc: A61K 38/00 20060101ALI20170323BHEP

Ipc: C12Q 1/68 20060101AFI20170323BHEP

17Q First examination report despatched

Effective date: 20180904

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20190702